Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
- $25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen the balance sheet.
- 04/28/2025
|
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
- We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches.
- 04/26/2025
|
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
- CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).
- 04/21/2025
|
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Matthew Parisi - KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 03/11/2025
|
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
- Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.
- 03/11/2025
|
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
- CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 AM ET (5:30 AM PT).
- 02/25/2025
|
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
- Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/05/2025
|
Exagen Inc. to Participate in Upcoming Investor Conferences
- CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
- 02/04/2025
|
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
- New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays, with a planned commercial launch in January 2025.
- 01/12/2025
|
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
- The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
- 12/12/2024
|
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
- Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
- 11/14/2024
|
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
- Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Participants Mark Massaro – BTIG Daniel Brennan - TD Cowen Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Third Quarter 2024 Earnings Call.
- 11/12/2024
|
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago.
- 11/12/2024
|
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
- CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
- 10/21/2024
|
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
- CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference, which takes place September 17-19, 2024, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Jeff Black, Exagen's Chief Financial Officer, will participate in a fireside chat on Wednesday, September 18th, at 9:45 AM ET.
- 09/04/2024
|
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
- After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 08/29/2024
|
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- 08/26/2024
|
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
- Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 08/09/2024
|
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 08/08/2024
|
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.
- 08/05/2024
|
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
- CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.
- 08/02/2024
|
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
- CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August.
- 08/01/2024
|
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
- CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).
- 07/22/2024
|
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 06/13/2024
|
Time to Play 5 Top-Ranked Stocks With Rising P/E?
- Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors' minds. This is because investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio.
- 06/10/2024
|
Time to Play 5 Top-Ranked Stocks With Rising P/E?
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
- 06/10/2024
|
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
- Exagen, Inc. (NASDAQ:XGN ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Operator Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
- 05/13/2024
|
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago.
- 05/13/2024
|
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
- CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024.
- 05/13/2024
|
Exagen to Announce First Quarter 2024 Results on May 13, 2024
- CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).
- 04/30/2024
|
Exagen Inc. Announces Changes to the Board of Directors
- CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
- 04/26/2024
|
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
- Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
- 03/18/2024
|
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.58 per share a year ago.
- 03/18/2024
|
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
- CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- 03/18/2024
|
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.
- 03/08/2024
|
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
- CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).
- 03/07/2024
|
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
- Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 02/06/2024
|
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
- CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
- 01/07/2024
|
Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded.
- 11/20/2023
|
Exagen Inc. Reports Strong Third Quarter 2023 Results
- SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.
- 11/13/2023
|
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
- SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis.
- 11/09/2023
|
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
- SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
- 10/30/2023
|
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
- SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.
- 09/28/2023
|
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a panel discussion on Tuesday, September 26th, at 8:45 AM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.
- 09/12/2023
|
Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript
- Start Time: 08:30 January 1, 0000 9:21 AM ET Exagen Inc. (NASDAQ:XGN ) Q2 2023 Earnings Conference Call August 07, 2023, 08:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Dustin Scaringe - William Blair Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call.
- 08/07/2023
|
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.78 per share a year ago.
- 08/07/2023
|
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
- SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).
- 07/25/2023
|
Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode.
- 05/15/2023
|
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.60 per share a year ago.
- 05/15/2023
|
XGN Stock: 14.89% Drop After Hours Explanation
- The stock price of Exagen Inc (NASDAQ: XGN) fell by 14.89% after hours in the most recent trading session. This is why.
- 03/20/2023
|
Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q4 2022 Results Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Kyle Mikson - Canaccord Dan Brennan - Cowen Paul Knight - KeyBanc Capital Markets Operator Greetings, and welcome to the Exagen Inc. Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 03/20/2023
|
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/20/2023
|
Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief Operating Officer Conference Call Participants Max Masucci - Cowen & Company Griffin Soriano - William Blair Kyle Mikson - Canaccord Genuity Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
- 11/14/2022
|
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
- SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
- 10/31/2022
|
Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Griffin Soriano - William Blair Ross Osborn - Cantor Fitzgerald Ryan Douglas Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022.
- 08/06/2022
|
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
- SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
- 07/21/2022
|
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2022 Results - Earnings Call Transcript
- Exagen Inc. (NASDAQ:XGN ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Brian Weinstein - William Blair Kyle Mikson - Canaccord Operator Greetings, ladies and gentlemen, and welcome to the Exagen, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded.
- 05/11/2022
|
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2022
|
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
- SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
- 04/25/2022
|
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
- Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
- 03/22/2022
|
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/22/2022
|
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
- SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
- 03/08/2022
|
Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript
- Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript
- 11/13/2021
|
Exagen: Q3 Earnings Insights
- Exagen (NASDAQ:XGN) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
- 11/10/2021
|
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
- SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30th, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Monday, September 27th at 2:40 PM EDT.
- 09/13/2021
|
Exagen Stock Gains As Q2 Financials Surpass Street Expectations
- Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the consensus of $11.48 million. Its flagship AVISE CTD test, including AVISE Lupus, raked in $10.4 million in sales with the 94% Y/Y growth, indicating an acceleration from ~22% YoY recorded in Q1 2021.
- 08/10/2021
|
XGN Stock Price Increases Over 34% Intraday: Why It Happened
- The stock price of Exagen Inc. (Nasdaq: XGN) increased by over 34% during intraday trading. This is why it happened.
- 08/10/2021
|
Exagen, Inc. (XGN) CEO Ron Rocca on Q2 2021 Results - Earnings Call Transcript
- Exagen, Inc. (XGN) CEO Ron Rocca on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.00% and 9.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Exagen Inc. Reports Second Quarter 2021 Results
- Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters
- 08/09/2021
|
Exagen Appoints Ana Hooker to Board of Directors
- SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independent member to its Board of Directors, effective July 29, 2021.
- 07/30/2021
|
Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
- SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference, which takes place August 10-12, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Thursday, August 12 at 12:00 PM EST.
- 07/29/2021
|
AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions
- SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found here: https://lupus.bmj.com/content/8/1/e000528.full. This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.
- 07/13/2021
|
Exagen Elects Frank Stokes to Board of Directors
- SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company's stockholders approved the election of Mr. Frank Stokes as an additional independent member to its Board of Directors at the Annual Meeting held on June 17, 2021. Mr. Stokes will also serve as Chair of the Audit Committee.
- 06/18/2021
|
Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
- SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, June 2 at 11:20 AM EDT.
- 05/24/2021
|
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript
- Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript
- 05/11/2021
|
Exagen Inc. Reports First Quarter 2021 Results
- Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters
- 05/11/2021
|
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
- The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases
- 05/04/2021
|
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
- SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely diagnosis and patient monitoring for Systemic Lupus Erythematosus (SLE).
- 05/03/2021
|
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
- SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
- 04/27/2021
|
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
- SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus.
- 03/29/2021
|
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million.
- 03/25/2021
|
Exagen Inc. Announces Pricing of Public Offering of Common Stock
- SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to be sold in the offering are to be sold by Exagen. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $60.1 million. In addition, Exagen has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock. The offering is expected to close on or about March 25, 2021, subject to the satisfaction of customary closing conditions.
- 03/22/2021
|
Exagen Inc. Announces Proposed Public Offering of Common Stock
- SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Exagen intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Exagen. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 03/22/2021
|
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript
- Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript
- 03/16/2021
|
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
- Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.18% and 16.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/16/2021
|
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
- Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters
- 03/16/2021
|
Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?
- Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 03/03/2021
|
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
- SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
- 03/02/2021
|
Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference
- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, March 3 at 4:00 pm EST.
- 02/22/2021
|
Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 17 at 3:00 PM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.
- 02/03/2021
|
Exagen Inc. Partners with Boston's Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
- SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center.
- 01/21/2021
|
Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results
- Record Testing Revenue, Adopters and AVISE CTD® Volumes
- 01/10/2021
|
Exagen Inc. To Participate in 2021 ICR Conference
- SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January 11-14, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Thursday, January 14 at 11:30 AM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through the ICR Conference site.
- 01/05/2021
|
Exagen Inc. Partners with Oregon's St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
- SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System, the largest provider of medical care in Central Oregon.
- 01/04/2021
|
Exagen (XGN) Looks Good: Stock Adds 9.3% in Session
- Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- 01/04/2021
|
Exagen Inc. to Participate in December Investor Conferences
- SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:
- 11/18/2020
|
Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management
- SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world's leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.
- 11/16/2020
|
Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript
- Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Exagen Inc. Reports Third Quarter 2020 Results
- Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing
- 11/10/2020
|
Exagen Inc. To Participate in November Investor Conferences
- SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following November investor conferences.
- 11/09/2020
|
Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
- SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women's Hospital in Boston, MA. The Brigham is acknowledged internationally for its expertise and innovation in patient care, biomedical research, and educational training programs for physicians, scientists, and health care professionals.
- 11/02/2020
|
Exagen to Announce Third Quarter Financial Results on November 10, 2020
- SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).
- 10/27/2020
|
